Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 932.25 INR
Change Today 0.00 / 0.00%
Volume 0.0
PIEL On Other Exchanges
Natl India
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

piramal enterprises ltd (PIEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/20/15 - 1,045
52 Week Low
10/17/14 - 664.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

piramal enterprises ltd (PIEL) Related Businessweek News

No Related Businessweek News Found

piramal enterprises ltd (PIEL) Details

Piramal Enterprises Limited primarily manufactures and sells own and traded bulk drugs and formulations in India and internationally. It operates through three segments: Healthcare, Financial Services, and Information Management. The company provides manufacturing services across the entire drug lifecycle ranging from drug discovery and development to commercial manufacturing of off-patent active pharmaceutical ingredients and finished dosage forms. It also manufactures and sells inhalation anaesthetics, such as Halothane, Isoflurane, and Sevoflurane; Propofol; and plasma volume expanders, including Polygeline. In addition, the company offers vitamins and nutrition, analgesics, dermatological, antacids, and cough and cold products under various brands, such as Lacto Calamine, Saridon, Supractiv Complete, Polycrol, I-Pill, I-Can, Jungle Magic, Tetmosol, and Triactiv. Further, it has four pipeline compounds in the fields of neurology, oncology, and cardiology. Additionally, the company offers Neuraceq, an imaging agent for positron emission tomography Imaging of Beta-amyloid neuritic plaques in the brain; BST-CarGel, a solution for cartilage regeneration; and focuses on developing and marketing healthcare solutions derived from natural sources, such as plants. It also offers finance to real estate developers; structured mezzanine funding to corporates in various sectors, including infrastructure; and data and analytics services to pharmaceutical, biotech, medical device, financial services, and managed care industries, as well as engages in NBFC operations. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

4,853 Employees
Last Reported Date: 07/13/15
Founded in 1947

piramal enterprises ltd (PIEL) Top Compensated Officers

Chairman, Member of Nomination & Remuneration...
Total Annual Compensation: 117.2M
Chief Financial Officer
Total Annual Compensation: 31.1M
Chief Operating Officer, Executive Director a...
Total Annual Compensation: 65.7M
Chief Executive Officer of Critical Care
Total Annual Compensation: --
Vice Chairperson
Total Annual Compensation: 45.7M
Compensation as of Fiscal Year 2015.

piramal enterprises ltd (PIEL) Key Developments

Piramal Healthcare Launches Stop AllerG in the Allergy Segment

Piramal Healthcare has launched `Stop AllerG', an anti-allergy OTC brand in Ahmedabad. Stop AllerG is a non-drowsy formula that provides relief in minutes and helps consumers stay active even when they suffer from symptoms such as watery eyes, watery nose, rapid sneezing and itchy throat. Stop AllerG is available at MRP of INR 60 for 5 tablets. The National Ambient Air Quality Standard for PM10 for residential, industrial and rural areas is 60 ug/m3.

Piramal Enterprises Seeking To Hive Off Critical Care Business

Piramal Enterprises Limited (BSE:500302) is weighing options to hive off its highly profitable critical care business. Piramal will further shrink to offering pharmaceutical solutions through contract development and manufacturing activities, the consumer products group and the imaging business which is steadily scaling traction.

Pharma Solutions Announces Revenue Results for the First Quarter of 2015

Pharma Solutions announced revenue results for the first quarter of 2015. For the quarter, the company reported that revenues grew by 27% year over year, to INR 5,670, primarily driven by growth in its Formulation business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIEL:IN 932.25 INR 0.00

PIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 4,781 INR -4.90
Biocon Ltd 441.60 INR +4.25
Cambrex Corp $47.86 USD -0.36
Jubilant Life Sciences Ltd 352.05 INR -2.85
Torrent Pharmaceuticals Ltd 1,615 INR +9.50
View Industry Companies

Industry Analysis


Industry Average

Valuation PIEL Industry Range
Price/Earnings 98.5x
Price/Sales 2.8x
Price/Book 1.3x
Price/Cash Flow 34.1x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIRAMAL ENTERPRISES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at